Amy Gilliland Joins the Board of Trustees
The Rett Syndrome Research Trust (RSRT) is thrilled to announce the appointment of Amy Gilliland, who currently serves as the President of General Dynamics Information Technology (GDIT), to its Board of Trustees. Amy's commitment to finding a cure for Rett syndrome is deeply personal, fueled by her daughter Ashley's diagnosis in 2015. Rett syndrome is a neurological disorder that affects hundreds of thousands globally, and Amy's new role signals a powerful step forward in the fight against this complex condition.
Dedication to the Mission
In her own words, Amy expressed, "I'm excited to join the Board of Trustees and engage with the Reverse Rett mission even more directly." As a parent of a child battling Rett syndrome, she echoes the passion and urgency felt by many associated with RSRT. Her belief that a cure is attainable fuels her work within the organization, and she is eager to contribute to the ongoing research aiming for solutions.
A Wealth of Experience
Amy brings a wealth of experience to the Board, having led GDIT, which oversees a substantial global technology portfolio valued at $8.7 billion. With over 25 years of seasoned public sector engagement—including nearly two decades with General Dynamics and service in the U.S. Navy—she is poised to offer invaluable insights and leadership. Her extensive background in strategizing and spearheading business growth will be essential in guiding RSRT's initiatives.
Advocating for Advancement
Since 2018, Amy has demonstrated her dedication to Rett syndrome awareness through Reverse Rett DC, an annual fundraising event that has successfully raised over $2 million for RSRT research. Her proactive approach exemplifies how personal experiences can foster meaningful contributions to the broader community.
Leadership Voices
Monica Coenraads, the Founder and Chief Executive Officer of RSRT, conveyed her enthusiasm, saying, "We are incredibly fortunate to have Amy join our Board. Her business acumen and remarkable commitment to helping those affected by Rett syndrome will be a significant asset." Amy's family shares her passion; her husband John, and their children—Patrick and Elizabeth—actively support the mission alongside her, illuminating the collective commitment to making a difference.
Understanding Rett Syndrome
Rett syndrome is caused by mutations in the MECP2 gene on the X chromosome. Although it primarily affects girls, boys can also be diagnosed. The disorder manifests typically between 12 and 18 months, leading to a range of symptoms that can rob children of speech, movement, and the ability to walk. While physical ailments are evident, it's believed that cognitive function remains largely unaffected, making the tragic outcome all the more poignant as these individuals require complete care into adulthood.
The Role of the Rett Syndrome Research Trust
Founded in 2008 in a humble setting, RSRT is dedicated to advocating for those with Rett syndrome. The organization is steadfast in its belief that the condition is reversible in laboratory settings, and with ongoing research and adequate funding, there is hope for translating these results into human therapies. With nearly $110 million raised over the years, RSRT is a leading force funding Rett research globally. The organization is eager to translate advancements into actual therapeutic diets, with multiple ongoing clinical trials aimed at benefiting those affected.
Future Directions
In 2024, RSRT launched a bold $40 million initiative called the "Roadmap to Cures," aimed at developing three new genetic medicines to clinical testing by 2028. The mission encompasses a clear goal: curing Rett syndrome and improving life quality for individuals and families impacted by the condition.
Frequently Asked Questions
What role does Amy Gilliland play in RSRT?
Amy Gilliland has joined the Board of Trustees at RSRT, bringing leadership experience and a personal commitment to the fight against Rett syndrome.
Why is Rett syndrome a focus for RSRT?
RSRT seeks to address Rett syndrome due to its profound impact—affecting thousands and being a reversible genetic disorder when approached with the right research and funding.
What initiatives are RSRT currently pursuing?
The organization is working on multiple clinical trials and has launched the "Roadmap to Cures" initiative to develop new genetic therapies.
How does Amy Gilliland’s family contribute to RSRT?
Amy's husband and children actively support fundraising efforts for RSRT, showcasing their family commitment to the cause.
What is the significance of Reverse Rett DC?
This event has raised over $2 million for RSRT and represents a pivotal fundraising effort led by Amy Gilliland since 2018.
